Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
All content curated by
story of the week
Published in Diabetes

Journal Scan / Research · September 04, 2024

Efficacy and Safety of Ultra–Rapid Acting vs Rapid-Acting Insulin Analogs in People With Type 1 or Type 2 Diabetes

Diabetes Technology & Therapeutics

 

Additional Info

Diabetes Technology & Therapeutics
Are New Ultra-Rapid-Acting Insulins Associated with Improved Glycemic Control and Reduced Hypoglycemia in Comparison to Conventional Rapid-Acting Insulins for Individuals with Type 1 and Type 2 Diabetes? A Systematic Review and Meta-Analysis
Diabetes Technol. Ther. 2024 Aug 01;26(8)575-586, R Villar-Taibo, A Galdón Sanz-Pastor, E Fernández-Rubio, D Barajas Galindo, A Simó Servat, FJ Ampudia-Blasco

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading